サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1563967

細胞株開発の世界市場

Cell Line Development

出版日
ページ情報
英文 193 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
細胞株開発の世界市場
出版日: 2024年09月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

細胞株開発の世界市場は2030年までに164億米ドルに達する見込み

2023年に91億米ドルと推定される細胞株開発の世界市場は、分析期間2023-2030年にCAGR 8.9%で成長し、2030年には164億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである哺乳類細胞株開発は、CAGR 9.6％を記録し、分析期間終了までに131億米ドルに達すると予測されています。非哺乳類細胞株開発セグメントの成長率は、分析期間中CAGR 6.2％と推定されます。

米国市場は25億米ドルと推定、中国はCAGR 8.2％で成長予測

米国の細胞株開発市場は2023年に25億米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年の分析期間においてCAGR 8.2％を辿り、2030年までに25億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.3%と7.2%と予測されています。欧州では、ドイツがCAGR約7.0%で成長すると予測されています。

世界の細胞株開発市場- 主な動向と促進要因

細胞株開発とは何か、なぜ現代のバイオテクノロジーで重要なのか？

細胞株開発はバイオテクノロジーにおける重要なプロセスであり、研究、治療、産業目的のために、均一な遺伝子構造を持つ細胞群-細胞株が生成されます。このプロセスは、バイオ医薬品、ワクチン、組換えタンパク質を製造するための基本であり、がん、自己免疫疾患、遺伝的欠損を含む様々な疾患の治療に用いられます。このような細胞株を作製するために、科学者たちは通常、組織や生物から細胞を分離し、高い生産性、安定性、環境ストレスへの耐性など、特定の性質を維持するように操作します。選択された細胞はin vitroで拡大され、特定の研究基準や製造基準を満たす能力があるかどうかスクリーニングされ、長期使用のために細胞株として樹立されます。やがてこれらの細胞株は、創薬、毒性試験、遺伝学的研究において不可欠なツールとなります。細胞株は生物学的メカニズムの研究において重要な役割を果たし、科学者たちに、タンパク質、遺伝子、その他の細胞成分の挙動を制御された環境で観察するためのプラットフォームを提供します。予測可能な方法で細胞を操作し調べるこの能力は、個別化医療、遺伝子治療、再生医療の進歩を加速させています。さらに、細胞株開発は、モノクローナル抗体のような複雑な分子である生物製剤の製造が再現可能でスケーラブルであることを保証します。その結果、医薬品から化粧品、農業に至るまで、多くの産業におけるバイオ製造プロセスの基盤として役立っています。

細胞株開発に影響を与える最新の技術進歩とは？

最近の技術の進歩は、細胞株開発のプロセスに革命をもたらしています。CRISPR-Cas9遺伝子編集ツールの統合により、細胞改変の精度が飛躍的に向上し、科学者は比類のない精度で特定の遺伝子をノックアウトしたり、挿入したりすることができるようになりました。これによって、特に精密な分子構造を必要とする治療用タンパク質の生産において、細胞株の応用範囲が広がった。さらに、自動化とロボット工学は開発プロセスにおいてますます重要になりつつあり、細胞株のハイスループット・スクリーニングを可能にしています。自動化システムは、数千の細胞をわずかな時間でスクリーニングする効率を向上させるだけでなく、人的ミスを減らし、結果の一貫性を高めることにもつながります。もう一つの変革的な技術は、人工知能（AI）と機械学習の応用です。これらのツールは現在、細胞の挙動を予測し、細胞培養条件を最適化し、高生産細胞株の選択プロセスを合理化するために採用されています。生物学的実験から生成された膨大なデータセットを分析することで、AIアルゴリズムはパターンを特定し、堅牢な細胞株の開発に必要な時間を大幅に短縮する推奨を行うことができます。このような計算ツールと生物学的システムの統合により、細胞株開発のスピードと精度が再定義されることが期待され、開発期間が50％短縮される可能性を示す研究もあります。生物製剤の需要が増加し、バイオ医薬品業界が市場投入までの時間を短縮することを推進する中で、このような技術革新は極めて重要です。

細胞株開発で直面する課題とその克服方法とは？

進歩にもかかわらず、細胞株開発のプロセスには、慎重な検討が必要な課題が山積しています。主な困難の一つは、遺伝的に同一の細胞であっても、細胞の挙動に固有のばらつきがあることです。このばらつきは、生物学的製剤のスケーラビリティーに影響を与えます。これに対処するため、開発者はクローン選択技術やマスター細胞バンクの設立に頼るようになってきており、そこでは安定した高性能のクローンが保存され、大量生産時に一貫した生産量を確保するために長期にわたってモニターされます。しかし、このような戦略をとっても、遺伝的ドリフトや不安定性のリスクは残るため、継続的なモニタリングと厳格な品質管理が必要となります。もう一つの重要なハードルは、細胞株開発の時間集約的な性質です。この長い時間枠は、臨床試験を遅らせ、医薬品開発プロセス全体を遅らせる可能性があります。企業は現在、タイムラインを早めるためのプロセス強化戦略に注力しています。例えば、シングルユース・バイオリアクターや灌流ベースの培養は、品質を損なうことなく細胞株の生産性を向上させるために使用されています。このような技術とともに、革新的な細胞株技術に由来するバイオ医薬品の迅速な承認経路をサポートするために、規制の枠組みも進化しています。しかし、製造管理及び品質管理に関する基準（GMP）を厳格に遵守する必要性は依然として重要なチェックポイントです。

細胞株開発市場はどのように進化し、何が市場促進要因となっているのか？

細胞株開発市場の成長にはいくつかの要因があり、それぞれがこれらのバイオテクノロジーツールに対する需要の急拡大に寄与しています。主な原動力の一つは、がんや糖尿病などの慢性疾患の蔓延が拡大していることであり、そのため製薬会社は生物学的療法に多額の投資を行うようになっています。モノクローナル抗体やその他の生物学的製剤が最前線の治療になりつつある今、効率的で生産性の高い細胞株の必要性はかつてないほど高まっています。もう一つの大きな原動力は、バイオシミラー（既に承認されている生物製剤に酷似した生物学的製剤）に対する需要の急増です。多くの大ヒット生物製剤の特許が切れる中、費用対効果の高いバイオシミラーの開発競争が、細胞株開発テクノロジーへの投資に拍車をかけています。個別化医療、特に腫瘍学の台頭も市場を押し上げています。個別化治療にはしばしば患者固有の細胞株の作製が必要であり、遺伝子工学やカスタム細胞培養技術の革新を促しています。さらに、がんに対するCAR-T療法のような細胞・遺伝子治療の出現は、標的治療に使用できる高度な細胞株の必要性を加速させています。さらに、バイオテクノロジーの研究開発に対する政府資金の増加と、自動化システムやAIを搭載したシステムの採用拡大が相まって、小規模なバイオテクノロジー企業の市場参入を可能にし、競争とイノベーションをさらに促進しています。最後に、化粧品、食品製造、環境科学などの非医薬品分野での細胞株の使用拡大により、これらの技術の範囲と応用が広がっており、細胞株開発はバイオテクノロジー業界の主要成長分野となっています。

調査対象企業の例（注目の44社）

  • Abzena PLC
  • American Type Culture Collection（ATCC）
  • Apath LLC
  • Bioceros
  • Catalent, Inc.
  • CELLforCURE
  • Cobra Biologics
  • Corning, Inc.
  • Cyagen US Inc.
  • Cytovance Biologics
  • Epistem Holdings PLC
  • EuBiologics Co., Ltd.
  • GE Healthcare
  • GVK Biosciences Private Limited
  • Hitachi Chemical Advanced Therapeutics Solutions, LLC
  • Lonza Group Ltd.
  • MilliporeSigma
  • NAEJA-RGM Pharmaceuticals, Inc.
  • Paragon Bioservices, Inc.
  • Patheon, Inc.
  • Promocell GmbH
  • Samsung BioLogics
  • Sartorius AG
  • Selexis SA
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP10946

Global Cell Line Development Market to Reach US$16.4 Billion by 2030

The global market for Cell Line Development estimated at US$9.1 Billion in the year 2023, is expected to reach US$16.4 Billion by 2030, growing at a CAGR of 8.9% over the analysis period 2023-2030. Mammalian Cell Line Development, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$13.1 Billion by the end of the analysis period. Growth in the Non-Mammalian Cell Line Development segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.5 Billion While China is Forecast to Grow at 8.2% CAGR

The Cell Line Development market in the U.S. is estimated at US$2.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.3% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.0% CAGR.

Global Cell Line Development Market - Key Trends and Drivers Summarized

What Is Cell Line Development and Why Does It Matter in Modern Biotechnology?

Cell line development is a crucial process in biotechnology where cell lines—groups of cells with a uniform genetic structure—are generated for research, therapeutic, and industrial purposes. This process is fundamental for producing biopharmaceuticals, vaccines, and recombinant proteins, which are used to treat a variety of diseases, including cancer, autoimmune disorders, and genetic deficiencies. To create these cell lines, scientists typically isolate cells from tissues or organisms and then engineer them to maintain specific properties, such as high productivity, stability, or resistance to environmental stress. The selected cells are expanded in vitro, screened for their ability to meet specific research or manufacturing criteria, and then established as cell lines for long-term use. Over time, these cell lines become integral tools in drug discovery, toxicity testing, and genetic research. Cell lines play a vital role in the study of biological mechanisms, offering scientists a platform to observe the behavior of proteins, genes, and other cellular components in controlled environments. This ability to manipulate and examine cells in a predictable manner has accelerated advancements in personalized medicine, gene therapy, and regenerative medicine. Moreover, cell line development ensures that the manufacturing of biologics—complex molecules like monoclonal antibodies—is reproducible and scalable. As a result, it serves as the foundation of biomanufacturing processes across numerous industries, from pharmaceuticals to cosmetics and agriculture.

What Are the Latest Technological Advancements Impacting Cell Line Development?

Recent advancements in technology are revolutionizing the process of cell line development. The integration of CRISPR-Cas9 gene-editing tools has drastically improved the precision of cell modifications, enabling scientists to knock out or insert specific genes with unmatched accuracy. This has broadened the scope of applications for cell lines, particularly in the production of therapeutic proteins that require precise molecular structures. Additionally, automation and robotics are becoming increasingly important in the development process, allowing for high-throughput screening of cell lines. Automated systems not only improve the efficiency of screening thousands of cells in a fraction of the time, but they also reduce human error, leading to higher consistency in results. Another transformative technology is the application of artificial intelligence (AI) and machine learning. These tools are now being employed to predict cell behavior, optimize cell culture conditions, and streamline the selection process for high-producing cell lines. By analyzing vast datasets generated from biological experiments, AI algorithms can identify patterns and make recommendations that significantly cut down the time needed to develop robust cell lines. This integration of computational tools with biological systems is expected to redefine the speed and accuracy of cell line development, with some studies indicating a potential 50% reduction in development timelines. Such innovations are critical as the demand for biologics grows and the biopharmaceutical industry pushes for faster time-to-market.

What Are the Challenges Faced in Cell Line Development and How Are They Overcome?

Despite the advancements, the cell line development process is still fraught with challenges that require careful consideration. One of the primary difficulties is the inherent variability in cellular behavior, even among genetically identical cells. This variability can lead to inconsistent production yields, which affects the scalability of biologic drugs. To address this, developers are increasingly relying on clonal selection techniques and the establishment of master cell banks, where stable, high-performing clones are stored and monitored over time to ensure consistent output during mass production. However, even with these strategies, the risk of genetic drift or instability remains, necessitating ongoing monitoring and stringent quality control. Another significant hurdle is the time-intensive nature of cell line development, which traditionally takes anywhere from 6 to 12 months. This extended timeframe can delay clinical trials and slow the overall drug development process. Companies are now focusing on process intensification strategies to accelerate timelines. For example, single-use bioreactors and perfusion-based cultures are being used to improve the productivity of cell lines without compromising quality. In tandem with these techniques, regulatory frameworks are evolving to support faster approval pathways for biopharmaceuticals derived from innovative cell line technologies. Yet, the need for stringent compliance with Good Manufacturing Practices (GMP) remains a critical checkpoint, as any lapse in quality can lead to costly setbacks in production.

How Is the Market for Cell Line Development Evolving, and What Are the Growth Drivers?

The growth in the cell line development market is driven by several factors, each contributing to the rapidly expanding demand for these biotechnological tools. One of the primary drivers is the increasing prevalence of chronic diseases, such as cancer and diabetes, which are prompting pharmaceutical companies to invest heavily in biologic therapies. With monoclonal antibodies and other biologics becoming frontline treatments, the need for efficient, high-producing cell lines has never been greater. Another significant driver is the surge in demand for biosimilars—biological products that are highly similar to already approved biologics. As patents for many blockbuster biologics expire, the race to develop cost-effective biosimilars is fueling investment in cell line development technologies. The rise of personalized medicine, particularly in oncology, is also pushing the market forward. Personalized therapies often require the production of patient-specific cell lines, driving innovations in genetic engineering and custom cell culture techniques. In addition, the emergence of cell and gene therapies, such as CAR-T therapy for cancer, is accelerating the need for advanced cell lines that can be used to deliver targeted treatments. Furthermore, increasing government funding for research and development in biotechnology, coupled with the growing adoption of automated and AI-powered systems, is enabling smaller biotech firms to enter the market, further driving competition and innovation. Lastly, the expanding use of cell lines in non-pharmaceutical sectors, such as cosmetics, food production, and environmental sciences, is broadening the scope and applications of these technologies, making cell line development a key growth area in the biotech industry.

Select Competitors (Total 44 Featured) -

  • Abzena PLC
  • American Type Culture Collection (ATCC)
  • Apath LLC
  • Bioceros
  • Catalent, Inc.
  • CELLforCURE
  • Cobra Biologics
  • Corning, Inc.
  • Cyagen US Inc.
  • Cytovance Biologics
  • Epistem Holdings PLC
  • EuBiologics Co., Ltd.
  • GE Healthcare
  • GVK Biosciences Private Limited
  • Hitachi Chemical Advanced Therapeutics Solutions, LLC
  • Lonza Group Ltd.
  • MilliporeSigma
  • NAEJA-RGM Pharmaceuticals, Inc.
  • Paragon Bioservices, Inc.
  • Patheon, Inc.
  • Promocell GmbH
  • Samsung BioLogics
  • Sartorius AG
  • Selexis SA
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Cell Line Development - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Biologics and Biosimilars Expands Market for Cell Line Development
    • Advancements in Gene Editing Technologies Propel Growth in Cell Line Engineering
    • Growing Adoption of Cell-Based Therapies Drives Demand for Efficient Cell Line Development
    • Automation in Cell Line Selection Spurs Efficiency and Scalability in Biopharmaceutical Production
    • Expansion of Monoclonal Antibody Production Boosts Market for Stable Cell Lines
    • Innovations in CRISPR and Gene Editing Create New Opportunities in Cell Line Development
    • Rising Investment in Cancer Research Fuels Demand for Custom Engineered Cell Lines
    • Growing Use of Cell Line Development in Vaccine Production Accelerates Market Growth
    • Advances in Single-Cell Analysis and Omics Technologies Propel Innovation in Cell Line Development
    • Emerging Applications in Gene Therapy and Regenerative Medicine Create New Growth Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cell Line Development Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cell Line Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for Cell Line Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Mammalian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Mammalian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Non-Mammalian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Non-Mammalian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Reagents & Media by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Reagents & Media by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Accessories & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Accessories & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Bioproduction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Bioproduction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Tissue Engineering & Regenerative medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Tissue Engineering & Regenerative medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World 7-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Toxicity Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World 7-Year Perspective for Toxicity Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 25: World 7-Year Perspective for Recombinant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hybridomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World 7-Year Perspective for Hybridomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Continuous Cell Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World 7-Year Perspective for Continuous Cell Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Primary Cell Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 31: World 7-Year Perspective for Primary Cell Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 35: USA 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 37: USA 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • CANADA
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Canada 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Canada 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Canada 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • JAPAN
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Japan 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 53: Japan 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Japan 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • CHINA
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 59: China 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 61: China 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • EUROPE
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Cell Line Development by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 65: Europe 7-Year Perspective for Cell Line Development by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Europe 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Europe 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 73: Europe 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • FRANCE
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 77: France 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 79: France 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • GERMANY
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Germany 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 85: Germany 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Germany 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 89: Germany 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • ITALY
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Italy 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Italy 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 95: Italy 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 97: Italy 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • UNITED KINGDOM
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 98: UK Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: UK 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 101: UK 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 103: UK 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UK 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of World 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 125: Rest of World 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 127: Rest of World 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of World 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030

IV. COMPETITION